Skip to main content

Advertisement

Fig. 2 | BMC Neurology

Fig. 2

From: Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke

Fig. 2

Changes in the Fugl-Meyer assessment (FMA) for Cerebrolysin (30 ml/day) and placebo at baseline (Day 8, T0), immediately after treatment (Day 29, T1) as well as two (Day 60, T2) and three (Day 90, T3) months after stroke onset. Analysis was based on the intention-to-treat (ITT) population using the last observation carried forward (LOCF) approach for missing data and the subgroup of patients with severe motor impairment (ITT-LOCF, FMA <50). The ITT-LOCF population included a total of 66 patients (Cerebrolysin n = 34, placebo n = 32), the subgroup a total of 37 patients (Cerebrolysin n = 20, placebo n = 17). Time courses (1) and improvements from baseline (2) are given for the total score of FMA (a), the upper limb subscore (b) and the lower limb subscore (c) for the total population (left panel) and the severe subgroup (right panel). d The simple regression analysis showed a significant relationship between FMA-T at T0 and T3 in both groups (Red dots and broken lines, Cerebrolysin group, d-1; placebo group, d-2). The improvement of FMA-T at T3 showed no relationship with baseline T0 scores in the Cerebrolysin group (d-1) (Blue dots), whereas the placebo group demonstrated a tendency of relationship between these two measures (d-2) (Blue dots and line). *p < 0.05 between time points in each group; **p < 0.05 between both groups; ***p < 0.05 between groups over time (repeated measures ANOVA)

Back to article page